Clinical Trial Update: Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining sorafenib for angiosarcoma that is locally advanced, metastatic, or unresectable. Sponsor: Centre Oscar Lambret.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Centre Oscar Lambret | Conditions: Sarcoma | Phase 2 | Status: UNKNOWN